Significant Ownership of BIOS Fund I, LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for BIOS Fund I, LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ John Fucci - John Fucci/Attorney-in-Fact
- Manager location
- Fort Worth, TX
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow BIOS Fund I, LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from BIOS Fund I, LP
Significant Ownership of BIOS Fund I, LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ACTU | Actuate Therapeutics, Inc. | Common Stock, par value $0.000001 per share | 50% | $112,734,207 | +$1,733,259 | 10,267,232 | +1.6% | AARON G.L. FLETCHER | 27 Jun 2025 |
| RNTX | Rein Therapeutics, Inc. | Common Stock, $0.001 par value per share | 10% | $10,136,753 | 7,797,502 | BIOS CAPITAL MANAGEMENT, LP | 06 May 2026 |
Schedules 13D/G Reported by BIOS Fund I, LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.